| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_677c37b8ad449440695cbc591cd07eb7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-2404 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-24 |
| filingDate |
2019-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a40cff4483aed434a9b299b9965c63b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8b85649ab81e1924fa0476bb781f021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc05de83f28aa890450df8a695443921 |
| publicationDate |
2021-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11130771-B2 |
| titleOfInvention |
Prodrugs of Naltrexone, Nalmefene and derivatives thereof |
| abstract |
A novel structure of an opioid antagonist is provided. One of the exemplary compounds of the present disclosure has the structure of Formula (II). The present disclosure overcomes the discomfort of conventional opioid antagonist due to rapid absorption and improves the patient compliance thereof. |
| priorityDate |
2018-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |